SPRY
Income statement / Annual
Last year (2023), ARS Pharmaceuticals, Inc.'s total revenue was $30,000.00,
a decrease of 97.72% from the previous year.
In 2023, ARS Pharmaceuticals, Inc.'s net income was -$54.37 M.
See ARS Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$30,000.00 |
$1.32 M |
$5.51 M |
$17.84 M |
$0.00 |
$0.00 |
| Cost of Revenue |
$73,000.00
|
$17.32 M
|
$20.27 M
|
$14.07 M
|
$1.55 M
|
$1.42 M
|
| Gross Profit |
-$43,000.00
|
-$16.00 M
|
-$14.77 M
|
$3.77 M
|
-$1.55 M
|
-$1.42 M
|
| Gross Profit Ratio |
-1.43
|
-12.16
|
-2.68
|
0.21
|
0
|
0
|
| Research and Development Expenses |
$20.27 M
|
$18.38 M
|
$20.27 M
|
$14.07 M
|
$21.51 M
|
$14.80 M
|
| General & Administrative Expenses |
$47.28 M
|
$18.46 M
|
$4.69 M
|
$4.23 M
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$47.28 M
|
$18.46 M
|
$4.69 M
|
$4.23 M
|
$1.02 M
|
$2.10 M
|
| Other Expenses |
$0.00
|
$974,000.00
|
-$789,000.00
|
-$596,000.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$67.55 M
|
$36.83 M
|
$24.96 M
|
$18.30 M
|
$22.52 M
|
$16.90 M
|
| Cost And Expenses |
$67.55 M
|
$36.83 M
|
$24.96 M
|
$18.30 M
|
$24.07 M
|
$18.32 M
|
| Interest Income |
$0.00
|
$0.00
|
$800,000.00
|
$400,000.00
|
$100,000.00
|
$43,000.00
|
| Interest Expense |
$0.00
|
$0.00
|
$106,000.00
|
$29,000.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$73,000.00
|
$319,000.00
|
$213,000.00
|
$1.71 M
|
$1.55 M
|
$1.42 M
|
| EBITDA |
-$67.45 M |
-$35.52 M |
-$19.24 M |
-$463,000.00 |
-$22.52 M |
-$16.90 M |
| EBITDA Ratio |
-2248.23
|
-26.64
|
-3.53
|
-0.03
|
0
|
0
|
| Operating Income Ratio |
-2250.67
|
-26.99
|
-3.53
|
-0.03
|
0
|
0
|
| Total Other Income/Expenses Net |
$13.16 M
|
$834,000.00
|
-$789,000.00
|
-$596,000.00
|
$100,000.00
|
$741,000.00
|
| Income Before Tax |
-$54.37 M
|
-$34.68 M
|
-$20.24 M
|
-$1.07 M
|
-$23.97 M
|
-$17.58 M
|
| Income Before Tax Ratio |
-1812.17
|
-26.35
|
-3.68
|
-0.06
|
0
|
0
|
| Income Tax Expense |
$0.00
|
-$694,000.00
|
-$230,558.00
|
-$200,297.00
|
$0.00
|
$0.00
|
| Net Income |
-$54.37 M
|
-$33.99 M
|
-$20.24 M
|
-$1.07 M
|
-$23.97 M
|
-$17.58 M
|
| Net Income Ratio |
-1812.17
|
-25.83
|
-3.68
|
-0.06
|
0
|
0
|
| EPS |
-0.57 |
-0.85 |
-0.7 |
-0.0307 |
-0.72 |
-0.53 |
| EPS Diluted |
-0.57 |
-0.85 |
-0.7 |
-0.0307 |
-0.72 |
-0.53 |
| Weighted Average Shares Out |
$95.22 M
|
$39.96 M
|
$28.87 M
|
$34.70 M
|
$33.07 M
|
$33.07 M
|
| Weighted Average Shares Out Diluted |
$95.22 M
|
$39.96 M
|
$28.87 M
|
$34.70 M
|
$33.07 M
|
$33.07 M
|
| Link |
|
|
|
|
|
|
